Lumida
/HRTX
⌘K
Heron Therapeutics Inc

Heron Therapeutics Inc

HRTX
$0.32USD-2.11%-0.01 today

MARKET CAP

59.9M

P/E (TTM)

FWD P/E

DAY RANGE

$0 – $0

52W RANGE

$0
$2

AI Summary

Stalk
Sell NowMedium

HRTX remains in a Stage 4 decline with a clear sequence of lower highs and lower lows. Price trades below the 9, 21, and 50 EMAs, which continue to slope down and act as resistance. Although a Post-Capitulation pattern indicates selling exhaustion at the recent low, the absence of any repair above intermediate EMAs confirms medium-term bearish control. The tradable side is bearish, and execution should involve selling now into failed retests of the short-term EMAs. Key risks include a decisive reclaim of the 9/21 EMAs and a sustained break above the 50 SMA that could invalidate the downtrend.

  • APONVIE sales grew 74% YoY, driving surgical NK-1 segment momentum
  • Tax Benefit Preservation Plan extended to July 2029 enhances cash runway
  • Q2 net loss of $5.5M and $0.03 EPS missed consensus
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$86.3M$107.7M$127.0M$144.3M$154.9M
YoY %-2.6%+24.7%+18.0%+13.6%+7.4%
P / Sales10.4x2.5x2.1x1.6x1.4x
EV / Sales12.0x4.5x3.8x3.3x2.8x
Gross Profit, Adj.$40.3M$52.8M$61.9M$105.6M$113.6M
YoY %-23.1%+30.9%+17.3%+70.6%+7.5%
Margin %46.7%49.0%48.8%73.2%73.3%
EV / Gross Profit25.7x9.2x7.9x4.5x3.8x
EBITDA, Adj.$-214.8M$-171.8M$-107.7M$-9.0M$-224,000
YoY %+4.7%+20.0%+37.3%+91.6%+97.5%
Margin %-248.8%-159.5%-84.8%-6.3%-0.1%
EV / EBITDA-4.8x-2.8x-4.5x-52.5x-1917.9x
EBIT$-217.8M$-174.7M$-110.6M$-11.5M$-2.5M
YoY %+4.5%+19.8%+36.7%+89.6%+78.0%
Margin %-252.3%-162.2%-87.1%-8.0%-1.6%
EV / EBIT-4.8x-2.8x-4.4x-41.1x-169.3x
Net Income$-220.7M$-182.0M$-110.6M$-13.6M$-20.2M
YoY %+2.9%+17.5%+39.3%+87.7%-48.7%
Net Margin-255.6%-169.1%-87.0%-9.4%-13.0%
EPS (GAAP)-$2.24-$1.67-$0.80-$0.09-$0.12
YoY %+10.4%+25.4%+52.1%+88.8%-33.3%